LENZ Therapeutics, Inc. – NASDAQ:LENZ
LENZ Therapeutics stock price today
$38.25
+6.93
+22.13%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
LENZ Therapeutics stock price monthly change
+48.93%
month
LENZ Therapeutics stock price quarterly change
+48.93%
quarter
LENZ Therapeutics key metrics
Market Cap | 847.57M |
Enterprise value | 821.86M |
P/E | -14.17 |
EV/Sales | N/A |
EV/EBITDA | -12.42 |
Price/Sales | N/A |
Price/Book | 3.95 |
PEG ratio | -0.14 |
EPS | -15.87 |
Revenue | N/A |
EBITDA | -62.28M |
Income | -117.36M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLENZ Therapeutics stock price history
LENZ Therapeutics stock forecast
LENZ Therapeutics financial statements
| Jun 2023 | 0 | -55.31M | |
|---|---|---|---|
| Sep 2023 | 0 | -22.48M | |
| Dec 2023 | 0 | -22.91M | |
| Mar 2024 | 0 | -16.64M |
| Sep 2025 | 5.35M | -3.77M | -70.56% |
|---|---|---|---|
| Dec 2025 | 7.41M | -3.86M | -52.11% |
| Mar 2026 | 5.19M | -5.51M | -106.05% |
| Jun 2026 | 8.68M | -4.63M | -53.39% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -0.25 | -0.19 |
|---|---|---|
| 2024-04-01 | -0.13 | -3.08 |
| 2024-05-08 | -0.84 | -3.53 |
| Jun 2023 | 287044000 | 62.89M | 21.91% |
|---|---|---|---|
| Sep 2023 | 266228000 | 62.20M | 23.37% |
| Dec 2023 | 188456000 | 4.87M | 2.59% |
| Mar 2024 | 217322000 | 19.15M | 8.81% |
| Jun 2023 | -13.65M | 72.22M | 124K |
|---|---|---|---|
| Sep 2023 | -9.40M | 63.87M | 8K |
| Dec 2023 | -45.87M | 47.08M | 66K |
| Mar 2024 | -23.93M | 18M | 171.26M |
LENZ Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 998009 | 0 |
| May 2024 | 34520 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | OLSSON SHAWN officer: Chief Commercial Officer | Stock Option (right to buy) | 3,333 | $2.08 | $6,933 | ||
Option | OLSSON SHAWN officer: Chief Commercial Officer | Common Stock | 3,333 | $2.08 | $6,933 | ||
Option | SCHIMMELPENNINK EVERT B. director, officer: President, C.. | Stock Option (right to buy) | 45,000 | $1.04 | $46,800 | ||
Option | SCHIMMELPENNINK EVERT B. director, officer: President, C.. | Common Stock | 45,000 | $1.04 | $46,800 | ||
Purchase | CHEVALLARD DANIEL R. officer: Chief Fi.. | Common Stock | 3,188 | $15.68 | $49,988 | ||
Purchase | MCCOLLUM JAMES W director | Common Stock | 31,332 | $15.99 | $501,093 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: | Common Stock | 933,038 | $15.03 | $14,023,561 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: | Common Stockj | 64,971 | $15.03 | $976,514 |
| Quarter | Transcript |
|---|---|
| Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
-
What's the price of LENZ Therapeutics stock today?
One share of LENZ Therapeutics stock can currently be purchased for approximately $38.25.
-
When is LENZ Therapeutics's next earnings date?
Unfortunately, LENZ Therapeutics's (LENZ) next earnings date is currently unknown.
-
Does LENZ Therapeutics pay dividends?
Yes, LENZ Therapeutics pays dividends and its trailing 12-month yield is 46.04% with 0% payout ratio. The last LENZ Therapeutics stock dividend of undefined was paid on 6 Sep 2025.
-
How much money does LENZ Therapeutics make?
LENZ Therapeutics has a market capitalization of 847.57M. LENZ Therapeutics made a loss 124.65M US dollars in net income (profit) last year or -$3.53 on an earnings per share basis.
-
What is LENZ Therapeutics's stock symbol?
LENZ Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "LENZ".
-
What is LENZ Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of LENZ Therapeutics?
Shares of LENZ Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
When LENZ Therapeutics went public?
LENZ Therapeutics, Inc. is publicly traded company for just a year since IPO on 22 Mar 2024.
LENZ Therapeutics company profile:
Exchange:
NASDAQ
Full time employees:
0
Industry:
Biotechnology
Sector:
Healthcare
LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
,
:
ISIN: US52635N1037
:
